ClearPoint Neuro (CLPT) Competitors

ClearPoint Neuro (NASDAQ:CLPT) and Cadre (NYSE:CDRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Is CLPT or CDRE more profitable?

Cadre has a net margin of 6.34% compared to ClearPoint Neuro's net margin of -59.64%. Cadre's return on equity of 12.88% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-59.64%	-62.10%	-38.39%
Cadre	6.34%	12.88%	6.06%

Do insiders & institutionals believe in CLPT or CDRE?

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 7.0% of ClearPoint Neuro shares are held by insiders. Comparatively, 37.0% of Cadre shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts rate CLPT or CDRE?

ClearPoint Neuro presently has a consensus target price of $25.00, suggesting a potential upside of 94.55%. Cadre has a consensus target price of $37.00, suggesting a potential upside of 2.38%. Given ClearPoint Neuro's higher probable upside, research analysts clearly believe ClearPoint Neuro is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cadre	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer CLPT or CDRE?

In the previous week, Cadre had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 4 mentions for Cadre and 3 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 1.42 beat ClearPoint Neuro's score of 1.19 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadre	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in CLPT or CDRE?

ClearPoint Neuro received 9 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 86.21% of users gave ClearPoint Neuro an outperform vote while only 55.17% of users gave Cadre an outperform vote.

Company	Underperform	Outperform
ClearPoint Neuro	Outperform Votes 25 86.21%	Underperform Votes 4 13.79%
Cadre	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%

Which has better earnings and valuation, CLPT or CDRE?

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$32.24M	11.16	-$22.09M	-$0.76	-16.91
Cadre	$559.81M	2.62	$38.64M	$0.95	38.04

Which has more risk and volatility, CLPT or CDRE?

ClearPoint Neuro has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Summary

Cadre beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.